Because Ad5-based immunotherapies may be of great value in the treatment of CHB in countries displaying elevated prevalence of Hepatitis B, it is important to evaluate whether infection by HBV may influence anti-Ad5 sero-prevalence. The gene discussed is PSEN2; the disease is infection.